Billionaire Martine Rothblatt's firm posts record $833m Q3
United Therapeutics reported Q3 revenue of $832.5M, up 4% YoY, beating estimates. Net income fell 24% to $258.6M due to higher R&D costs. Tyvaso DPI sales grew 13%. The company agreed to pay $525M to Pfizer's Arena unit to end royalties on ralinepag. Shares rose 5.9% post-results.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh guidance on revenue growth, cash position, and buyback activity, influencing short‑term price action.
Market read
The report moves United Therapeutics stock and may affect peer biotech stocks, while the buyback signals confidence to investors.
What to watch
The $525 m royalty payment to Arena/Pfizer and pending FDA decisions may weigh on cash flow later.
Background
United Therapeutics, founded by Martine Rothblatt, is a specialty‑drug company focused on pulmonary arterial hypertension and related therapies.
Ticker impact
United Therapeutics reported record Q3 revenue beating forecasts, with a 5.9% share rise and a $2 bn buyback program, providing fresh earnings data.
likely modest upside as market prices the revenue beat and new buyback tranche
Revenue beat, cash surplus, and a fresh $2 bn buyback program create buying pressure; EPS miss may limit upside but not reverse the trend.
Market effects
Biotech/pharma sector may see broader rally on strong specialty‑drug revenue growth.
U.S. healthcare stocks could benefit from the earnings beat and buyback news.
Limited to investors focused on U.S. biotech and specialty‑drug markets.
Counterpoint
EPS miss and higher R&D spend could signal margin pressure, suggesting caution.
Key entities
- ExecutiveMartine Rothblatt
Founder, Chairperson and CEO of United Therapeutics.
- CounterpartyArena Pharmaceuticals (Pfizer unit)
Recipient of a $525 m royalty settlement.
